News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

July 14, 2022 Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting
July 6, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2022 Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
June 10, 2022 Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
June 7, 2022 Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
June 6, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2022 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
June 1, 2022 Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
May 12, 2022 Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
May 6, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)